Most Common Long-Term Side Effects Reported by Patients
Keytruda (pembrolizumab), a PD-1 inhibitor immunotherapy, can trigger immune-related adverse events (irAEs) that persist or emerge months to years after treatment ends. These occur because the drug ramps up the immune system, sometimes causing it to attack healthy tissues. Endocrinopathies like hypothyroidism or hyperthyroidism affect up to 20-30% of patients and often require lifelong hormone replacement.[1] Pneumonitis, an inflammation of the lung tissue, shows up in 3-5% of cases but can lead to permanent scarring or fibrosis in severe instances.[2]
Why Do Endocrine Issues Last So Long?
The thyroid gland is hit hardest; damage from irAEs destroys hormone-producing cells, leading to permanent hypothyroidism in about 10-15% of affected patients. Adrenal insufficiency or type 1 diabetes mellitus can also develop late, sometimes over a year post-treatment, with patients needing daily steroids or insulin indefinitely.[3] Clinical data from KEYNOTE trials show these resolve in under half of cases, with others becoming chronic.[1]
Skin and Organ Damage That Sticks Around
Chronic skin reactions, such as vitiligo or lichenoid dermatitis, persist in 5-10% of users, causing ongoing pigmentation loss or rashes.[4] Colitis or hepatitis can evolve into inflammatory bowel disease or liver fibrosis, reported in post-marketing surveillance as requiring long-term immunosuppressants like steroids.[2] Rare but serious cases include myocarditis or neuropathy, with some patients facing permanent heart rhythm issues or nerve damage years later.[3]
Risks in Combination Therapies
When paired with drugs like chemotherapy or lenvatinib, long-term effects intensify—thyroid dysfunction jumps to 40-50%, and cardiac events like pericarditis become more frequent and enduring.[5] Follow-up studies on melanoma patients show 15-20% still managing irAEs five years out.[1]
Monitoring and Patient Concerns
Patients often search for ways to spot late-onset issues; regular bloodwork for thyroid function and imaging for lungs or heart are standard for years post-treatment. No full reversal exists for many irAEs, so oncologists stress early steroids, but overuse risks infections.[2] Real-world data highlights fatigue and joint pain as underreported long-haulers, impacting quality of life.[4]
[1]: FDA Keytruda Label
[2]: ASCO Guidelines on irAEs
[3]: NEJM Review on Checkpoint Inhibitors
[4]: JAMA Dermatology Study
[5]: KEYNOTE-189 Trial Data